Abstract
Tumour development is a multi-step process during which genetic and epigenetic events determine the transition from a normal to a malignant cellular state. In the past decade, extensive effort has been made not only to define the molecular mechanisms underlying progression to malignancy but also to predict the development of the disease and to identify possible molecular targets for therapy. Common to most tumours, several regulatory circuits are altered during multistage tumour progression, most importantly, the control of proliferation, the balance between cell survival and programmed cell death (apoptosis), the communication with neighbouring cells and the extracellular matrix, the induction of tumour neovascularization (angiogenesis) and, finally, tumour cell migration, invasion and metastatic dissemination. De-regulation of each of these processes represents a rate-limiting step for tumour development and, hence, has to be achieved by tumour cells in a highly selective manner during tumour progression.
In this review we summarize recent advances in cancer research that have provided new insights in the molecular mechanisms underlying the transition between one tumour stage and the next and into their concerted action during tumour progression. Cultured human tumour cell lines as well as transgenic and knock-out mouse models of tumorigenesis have been instrumental in these experimental approaches. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ali IU, Schriml LM and Dean M (1999) Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91: 1922–1932
Baserga R (1999) The IGF-I receptor in cancer research. Exp Cell Res 253: 1–6
Becker D, Meier CB and Herlyn M (1989) Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. Embo J 8: 3685–3691
Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S and Wright WE (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349–352
Bouck N, Stellmach V and Hsu SC (1996) How tumors become angiogenic. Adv Cancer Res 69: 135–174
Brooks PC, Silletti S, von Schalscha TL, Friedlander M and Cheresh DA (1998) Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92: 391–400
Bullions LC and Levine AJ (1998) The role of beta-catenin in cell adhesion, signal transduction, and cancer. Curr Opin Oncol 10: 81–87
Cahill DP, Lengauer C, Yu J, Riggins GJ, Wilson JK, Markowitz SD, Kinzler KW and Vogelstein B (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392: 300–303
Chin L, Pomerantz J and DePinho RA (1998) The INK4a/ARF tumor suppressor: one gene – two products – two pathways. Trends Biochem Sci 23: 291–296
Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW and DePinho RA 1999a) p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97: 527–538
Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O’Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD and DePinho RA 1999b) Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468–472
Christofori G and Semb H (1999) The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 24: 73–76
Christofori G, Naik P and Hanahan D (1994) A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369: 414–418
Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH and Hanahan D (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 1382–1397
Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P and Matrisian LM (1999) The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18: 2883–2891
Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP and Bouck N (1998) Thrombospondin-1 is a major activator of TGF-betal in vivo. Cell 93: 1159–1170
Dameron KM, Volpert OV, Tainsky MA and Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582–1584
Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A and Lee EY (1999) DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18: 7883–7899
Downward J (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10: 262–267
Duval A, Iacopetta B, Ranzani GN, Lothe RA, Thomas G and Hamelin R (1999) Variable mutation frequencies in coding repeats of TCF-4 and other target genes in colon, gastric and endometrial carcinoma showing microsatellite instability. Oncogene 18: 6806–6809
Eastman Q and Grosschedl R (1999) Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr Opin Cell Biol 11: 233–240
Ewald D, Li M, Efrat S, Auer G, Wall RJ, Furth PA and Hennighausen L (1996) Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 273: 1384–1386
Fedi P, Tronick SR and Aaronson SA (1997) Growth factors. In: Cancer Medicine, Holland JF Bast RC Morton DL Frei E Kufe DW Weichselbaum RR (eds) pp 41–64. Williams and Wilkins: Baltimore, MD
Felsher DW and Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4: 199–207
Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77: 527–543
Ferrara N and Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5: 1359–1364
Fingleton BM, Heppner Goss KJ, Crawford HC and Matrisian LM (1999) Matrilysin in early stage intestinal tumorigenesis. Apmis 107: 102–110
Folkman J (1990) What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82: 4–6
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27–31
Greenberg RA, Chin L, Femino A, Lee KH, Gottlieb GJ, Singer RH, Greider CW and DePinho RA (1999) Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 97: 515–525
Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A and Reeve AE (1998) E-cadherin germline mutations in familial gastric cancer. Nature 392: 402–405
Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW and Weinberg RA (1999) Creation of human tumour cells with defined genetic elements. Nature 400: 464–468
Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364
Harrington EA, Bennett MR, Fanidi A and Evan GI (1994) c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. Embo J 13: 3286–3295
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509–1512
Herman JG (1999) Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol 9: 359–367
Holt SE and Shay JW (1999) Role of telomerase in cellular proliferation and cancer. J Cell Physiol 180: 10–18
Hueber AO, Zornig M, Lyon D, Suda T, Nagata S and Evan GI (1997) Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278: 1305–1309
Huebner K, Garrison PN, Barnes LD and Croce CM (1998) The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet 32: 7–31
Jaattela M (1999) Escaping cell death: survival proteins in cancer. Exp Cell Res 248: 30–43
Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL and Bouck N (2000) Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6: 41–418
Karlseder J, Broccoli D, Dai Y, Hardy S and de Lange T (1999) p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283: 1321–1325
Kinzler KW and Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87: 159–170
Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B and Clevers H (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science 275: 1784–1787
Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, Weinberg RA and Jaenisch R (1995) Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81: 197–205
Lengauer C, Kinzler KW and Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396: 643–649
Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M and Lowe SW (1998) Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 12: 3008–3019
Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, Wilson KS, White MA, Wright WE and Shay JW (1999) Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 21: 115–118
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787–1790
Pelengaris S, Littlewood T, Khan M, Elia G and Evan G (1999) Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3: 565–577
Peltomaki P and de la Chapelle A (1997) Mutations predisposing to hereditary nonpolyposis colorectal cancer. Adv Cancer Res 71: 93–119
Perl AK, Wilgenbus P, Dahl U, Semb H and Christofori G (1998) A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392: 190–193
Polakis P (1997) The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1332: F127–147
Rabbani SA (1998) Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo 12: 135–142
Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL and Bedi A (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14: 34–44
Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275: 1790–1792
Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C and DePinho RA (1999) Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96: 701–712
Schwartz S Jr, Yamamoto H, Navarro M, Maestro M, Reventos J and Perucho M (1999) Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 59: 2995–3002
Semenza GL (1999) Regulation of mammalian O2homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551–578
Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p161INK4a. Cell 88: 593–602
Sherr CJ (1998) Tumor surveillance via the ARF-p53 pathway. Genes Dev 12: 2984–2991
Shtutman M, Zhurinsky J, Simcha I, Albanese C, D’Amico M, Pestell R and Ben-Ze’ev A (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522–5527
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP and Mak TW (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29–39
Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ and Werb Z (1999) The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98: 137–146
Tetsu O and McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422–426
Toyota M and Issa JP (1999) CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 9: 349–357
Wilson CL, Heppner KJ, Labosky PA, Hogan BL and Matrisian LM (1997) Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 94: 1402–1407
Yarden Y and Ullrich A (1988) Growth factor receptor tyrosine kinases. Annu Rev Biochem 57: 443–478
Zhang X, Mar V, Zhou W, Harrington L and Robinson MO (1999) Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 13: 2388–2399
Zhu J, Woods D, McMahon M and Bishop JM (1998) Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 12: 2997–3007
Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ and Roussel MF (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424–2433
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Compagni, A., Christofori, G. Recent advances in research on multistage tumorigenesis. Br J Cancer 83, 1–5 (2000). https://doi.org/10.1054/bjoc.2000.1309
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1309
Keywords
This article is cited by
-
Bidirectional promoters: an enigmatic genome architecture and their roles in cancers
Molecular Biology Reports (2021)
-
An immature B cell population from peripheral blood serves as surrogate marker for monitoring tumor angiogenesis and anti-angiogenic therapy in mouse models
Angiogenesis (2015)
-
Expression of PTTG1 and PTEN in endometrial carcinoma: correlation with tumorigenesis and progression
Medical Oncology (2012)
-
Metabolism and cancer: the circadian clock connection
Nature Reviews Cancer (2009)
-
Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis
Cancer Gene Therapy (2007)